Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | MMP8 | P22894 | 4/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.50 |
| ▸ | KDM4A | O75164 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4780368 | 0.96 | KMT2A (0.53) | CYP2D6CYP2C9CYP2C19KMT2AMMP8 | |
| SCHEMBL4780175 | 0.87 | LMNA (0.57) | CYP2D6CYP2C9CYP2C19KMT2AMMP8 | |
| SCHEMBL27742525 | 0.83 | LMNA (0.59) | CYP2D6CYP2C9CYP2C19KMT2AMMP8 | |
| SCHEMBL4779824 | 0.83 | LMNA (0.59) | CYP2D6CYP2C9CYP2C19KMT2AMMP8 | |
| SCHEMBL7435848 | 0.82 | CYP2D6 (0.51) | CYP2D6CYP2C9CYP2C19KMT2AMMP8 | |
| SCHEMBL12295586 | 0.79 | CYP2D6 (0.54) | CYP2D6CYP2C9CYP2C19KMT2AMMP8 | |
| SCHEMBL3780973 | 0.79 | LMNA (0.49) | CYP2D6CYP2C9CYP2C19KMT2AMMP8 | |
| SCHEMBL3780976 | 0.79 | LMNA (0.49) | CYP2D6CYP2C9CYP2C19KMT2AMMP8 | |
| SCHEMBL162806 | 0.79 | HDAC1 (0.62) | KMT2AL3MBTL1LMNAKDM4ECA12 | |
| SCHEMBL4779947 | 0.77 | PLAAT5 (0.71) | L3MBTL1LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080319065-A1 | Systemic and Intrathecal Effects of a Novel Series of Phospholipase A2 Inhibitors on Hyperalgesia and Spinal Pge2 Release | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-12-25 | — | — | US | disclosed |
| EP-1937247-A2 | SYSTEMIC AND INTRATHECAL EFFECTS OF A NOVEL SERIES OF PHOSPHOLIPASE A2 INHIBITORS ON HYPERALGESIA AND SPINAL PGE2 RELEASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007022443-A2 | SYSTEMIC AND INTRATHECAL EFFECTS OF A NOVEL SERIES OF PHOSPHOLIPASE A2 INHIBITORS ON HYPERALGESIA AND SPINAL PGE2 RELEASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319065-A1 | Systemic and Intrathecal Effects of a Novel Series of Phospholipase A2 Inhibitors on Hyperalgesia and Spinal Pge2 Release | PLA2G4A, PLA2G4B, PLA2G2A | CYP2D6 2122/4885CYP2C9 2130/4885CYP2C19 2540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.